Special Issues

Non-coding RNAs on the Clinical Application of Solid Cancers

Submission Deadline: 21 September 2023 (closed) View: 4

Guest Editors

Nicola Silvestris, Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy. Email: nsilvestris@unime.it;

Pascal H. G. Duijf, Translational Research Institute, University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia. Email: pascal.duijf@qut.edu.au;

Afshin Derakhshani, Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta T2N 4N1, Canada. Email: afshin.derakhshani@ucalgary.ca;

Behzad Baradaran, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Email: baradaranb@tbzmed.ac.ir;

Mahdi Abdoli Shadbad, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Email: abdolim@tbzmed.ac.ir;

Nima Hemmat, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Email: hemmatm@tbzmed.ac.ir

Summary

Non-coding RNAs are a group of RNA molecules that do not serve as a protein templet. It is well-established that non-coding RNAs substantially regulate post-transcriptional gene expression. Non-coding RNAs regulate various cellular processes, and dysregulated RNA expression has been implicated in cancer development. Long non-coding RNA (lncRNA), circular RNA (circRNA), and microRNA (miR) belong to the non-coding RNAs that have pivotal roles in cancer development and metastasis. Growing evidence has shown that specific circRNAs can sponge specific microRNAs, regulating the expression of tumor-suppressive and oncogenes. Since miRs can regulate a wide range of mRNA expression, identifying these axes can serve as a potential therapeutic avenue to enhance the chemo and radiosensitivity of tumoral cells, increase the efficacy of immunotherapeutic approaches, and inhibit tumor growth and metastasis. In this regard, the application of system biology approaches and advanced bioinformatic investigations, e.g., single-cell RNA sequencing, have further provided novel insights into the significance of human and viral non-coding RNAs in cancer development.

In this special issue, we welcome narrative reviews, original works, systematic reviews, in-silico investigations, and scoping reviews studying the significance of human and viral non-coding RNAs and the related axes in human cancer development. Also, we welcome the submissions highlighting the potentialities of these non-coding RNAs in enhancing the treatment of human cancers.


Keywords

Non-coding RNAs, Neoplasms, Bioinformatics, Cancer treatment, Post-transcriptional regulation

Published Papers


  • Open Access

    ARTICLE

    Circ_0053943 complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of Epidermal growth factor receptor

    ANDI ZHAO, YUE WANG, ZIJIN WANG, QING SHAO, QI GONG, HUI ZHU, SHIYA SHEN, HU LIU, XUEJUAN CHEN
    Oncology Research, Vol.32, No.5, pp. 983-998, 2024, DOI:10.32604/or.2024.045972
    (This article belongs to the Special Issue: Non-coding RNAs on the Clinical Application of Solid Cancers)
    Abstract Numerous studies have characterized the critical role of circular RNAs (circRNAs) as regulatory factors in the progression of multiple cancers. However, the biological functions of circRNAs and their underlying molecular mechanisms in the progression of uveal melanoma (UM) remain enigmatic. In this study, we identified a novel circRNA, circ_0053943, through re-analysis of UM microarray data and quantitative RT-PCR. Circ_0053943 was found to be upregulated in UM and to promote the proliferation and metastatic ability of UM cells in both in vitro and in vivo settings. Mechanistically, circ_0053943 was observed to bind to the KH1 and KH2 domains of insulin-like… More >

    Graphic Abstract

    <i>Circ_0053943</i> complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of <i>Epidermal growth factor receptor</i>

  • Open Access

    ARTICLE

    miR-125b reverses cisplatin resistance by regulating autophagy via targeting RORA/BNIP3L axis in lung adenocarcinoma

    LEI LIU, NA GUO, XIANGLING LI, QIAN XU, RUILONG HE, LIMIN CHENG, CHUNYAN DANG, XINYU BAI, YIYING BAI, XIN WANG, QIANHUI CHEN, LI ZHANG
    Oncology Research, Vol.32, No.4, pp. 643-658, 2024, DOI:10.32604/or.2023.044491
    (This article belongs to the Special Issue: Non-coding RNAs on the Clinical Application of Solid Cancers)
    Abstract The platinum-based chemotherapy is one of the most frequently used treatment protocols for lung adenocarcinoma (LUAD), and chemoresistance, however, usually results in treatment failure and limits its application in the clinic. It has been shown that microRNAs (miRNAs) play a significant role in tumor chemoresistance. In this study, miR-125b was identified as a specific cisplatin (DDP)-resistant gene in LUAD, as indicated by the bioinformatics analysis and the real-time quantitative PCR assay. The decreased serum level of miR-125b in LUAD patients was correlated with the poor treatment response rate and short survival time. MiR-125b decreased the… More >

Share Link